{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:09:18Z","timestamp":1761498558904,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.beha.2018.09.015","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:25:21Z","timestamp":1537835121000},"page":"367-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Should immunologic strategies be incorporated into frontline ALL therapy?"],"prefix":"10.1016","volume":"31","author":[{"given":"Cecilie Utke","family":"Rank","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.beha.2018.09.015_bib1","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.09.015_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.09.015_bib3","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2018.09.015_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.V80.7.1813.1813","article-title":"Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome","volume":"80","author":"Taylor","year":"1992","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.09.015_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.leu.2400959","article-title":"The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties","volume":"12","author":"Chessells","year":"1998","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2018.09.015_bib6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.leu.2402006","article-title":"Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate\/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study","volume":"15","author":"Petersdorf","year":"2001","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2018.09.015_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.09.015_bib8","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","article-title":"Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia","volume":"20","author":"Linker","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2018.09.015_bib9","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.beha.2018.09.015_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of cancer and leukemia group B study 19802","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.beha.2018.09.015_bib11","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.27901","article-title":"Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial","volume":"119","author":"Lamanna","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2018.09.015_bib12","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.09.015_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2011.09020.x","article-title":"Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008","volume":"157","author":"Toft","year":"2012","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.beha.2018.09.015_bib14","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2018.09.015_bib15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","article-title":"Treatment of adult ALL according to protocols of the German multicenter study group for adult ALL (GMALL)","volume":"14","author":"Gokbuget","year":"2000","journal-title":"Hematol Oncol Clin N Am"},{"issue":"10","key":"10.1016\/j.beha.2018.09.015_bib16","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","article-title":"Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial","volume":"104","author":"Hunault","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2018.09.015_bib17","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.09.015_bib18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2018.09.015_bib19","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in The Netherlands","volume":"18","author":"de Bont","year":"2004","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2018.09.015_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.20749","article-title":"Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials","volume":"48","author":"Ramanujachar","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.beha.2018.09.015_bib21","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.09.015_bib22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12562","article-title":"Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"96","author":"Toft","year":"2016","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2018.09.015_bib23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2018.09.015_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2018.09.015_bib25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.09.015_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2018.09.015_bib27","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2018.09.015_bib28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2018.09.015_bib29","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.beha.2018.09.015_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.beha.2018.09.015_bib31","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2018.09.015_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.09.015_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/jayao.2011.1511","article-title":"Intergroup Trial C10403: a pediatric treatment approach to improve outcomes in adolescents and young adults with acute lymphoblastic leukemia","volume":"1","author":"Breitenbach","year":"2011","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.09.015_bib34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.09.015_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"224","key":"10.1016\/j.beha.2018.09.015_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9967","key":"10.1016\/j.beha.2018.09.015_bib37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beha.2018.09.015_bib38","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.beha.2018.09.015_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.beha.2018.09.015_bib40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2018.09.015_bib41","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2018.09.015_bib42","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.beha.2018.09.015_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.09.015_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.beha.2018.09.015_bib45","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.beha.2018.09.015_bib46","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.09.015_bib47","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","article-title":"Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia","volume":"102","author":"Gokbuget","year":"2017","journal-title":"Haematologica"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:07Z","timestamp":1761498307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1521692618300896"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.09.015","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should immunologic strategies be incorporated into frontline ALL therapy?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}